Tag Archives: Letairis

October, 2015

  • 5 October

    FDA Approves Gilead’s Letairis with Tadalafil for Treatment of PAH

    FOSTER CITY, Calif.–(BUSINESS WIRE)–Oct. 2, 2015– Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Letairis® (ambrisentan) in combination with tadalafil for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to reduce the risks of disease progression and hospitalization for worsening PAH, and to …

April, 2015